IMMUNOCYTOTHERAPY FOR RECURRENT ABORTION OF ALLOIMMUNE GENESIS


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To discuss the controversial issues associated with the use of immunomodulatory therapy for recurrent abortion of alloimmune genesis. Material and methods. The review included the data of foreign and Russian papers published in the past 10 years and found on this topic. Results. Despite long-term clinical experience, there are no ideas on the mechanisms of immunomodulatory effects of immunocytotherapy, its clear indications, or uniform recommendations for the frequency of its procedures and for the dosage and routes of administration of a partner’s allogeneic cells. Conclusion. The review reveals the reasons for conflicting opinions concerning the efficiency of immunocytotherapy for recurrent abortion of alloimmune genesis and provides evidence for the need to continue investigations in this area.

Full Text

Restricted Access

About the authors

Victoria A. Saribegova

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: saribegova_v@rambler.ru
Graduate student, Department of Pregnancy Loss Prevention and Therapy Moscow 117997, Ac. Oparina str. 4, Russia

Nana K. Tetruashvili

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: tetrauly@mail.ru
Doctor of Medicine, Head of the Department of Pregnancy Loss Prevention and Therapy Moscow 117997, Ac. Oparina str. 4, Russia

Lyubov V. Krechetova

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: k_l_v_@mail.ru
Ph.D. in medical sciences, Head of Laboratory of Clinical Immunology Moscow 117997, Ac. Oparina str. 4, Russia

Valentina V. Vtorushina

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: vtorushina@inbox.ru
Ph.D. in medical sciences, doctor of laboratory diagnostics in Laboratory of Clinical Immunology Moscow 117997, Ac. Oparina str. 4, Russia

Anna A. Agadjanova

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: tetrauly@mail.ru
Doctor of Medicine, leading researcher of the Department of Pregnancy Loss Prevention and Therapy Moscow 117997, Ac. Oparina str. 4, Russia

References

  1. Сидельникова В.М., Сухих Г.Т. Невынашивание беременности. Руководство для практикующих врачей. М.: МИА; 2011.
  2. Hyde K.J., Andelin C.O., Schust D.J. Immunology of isolated and recurrent spontaneous pregnancy loss. Glob. Libr. Women’s Med.; 2008.
  3. Левкович М.А., Линде В.А., Андреева В.О., Плахотя Т.Г., Нефедова Д.Д. Иммуно-гормональные взаимодействия в генезе невынашивания беременности ранних сроков. Акушерство и гинекология. 2012; 8-1: 10-4.
  4. Winger E.E., Reed J.L. Debate: Should immunotherapy be used? Lymphocyte immunization therapy: yes. In: Carp H.J.A., ed. Recurrent pregnancy loss: causes, controversies, and treatment. 2nd ed. CRC Press; 2014: 249.
  5. Li J., Chen Y., Liu C., Hu Y., Li L. Intravenous immunoglobulin treatment for repeated IVF/ICSI failure and unexplained infertility: a systematic review and a meta-analysis. Am. J. Reprod. Immunol 2013; 70(6): 434-47.
  6. Шмагель К.В., Черешнев В.А. Иммунитет беременной женщины. М.: Медицинская книга; 2003. 225c.
  7. Батрак Н.В., Малышкина А.И., Крошкина Н.В. Иммунологические аспекты привычного невынашивания беременности. ФГБУ Ивановский научно-исследовательский институт материнства и детства им. В.Н. Городкова Минздрава России, ГБОУ ВПО Ивановская государственная медицинская академия Минздрава России; 2015.
  8. Brownfoot F.C., Tong S., Hannan N.J., Binder N.K., Walker S.P., Cannon P. et al. Effects of pravastatin on human placenta, endothelium, and women with Ssevere preeclampsia. Hypertension. 2015; 66(3): 687-97.
  9. Brogin Moreli J., Cirino Ruocco A.M., Vernini J.M., Rudge M.V., Calderon I.M. Interleukin 10 and tumor necrosis factor-alpha in pregnancy: aspects of interest in clinical obstetrics. ISRN Obstet. Gynecol. 2012; 2012: 230742.
  10. Farquharson R.G., Stephenson M.D., eds. Early pregnancy. Cambridge University Press; 2012.
  11. Kheshtchin N., Gharagozloo M., Andalib A., Ghahiri A., Maracy M.R., Rezaei A. The expression of Th1- and Th2-related chemokine receptors in women with recurrent miscarriage: the impact of lymphocyte immunotherapy. Am. J. Reprod. Immunol. 2010; 64(2): 104-12.
  12. Clark D.A. Cell surface CD200 may predict efficacy of paternal mononuclear leukocyte immunotherapy in treatment of human recurrent pregnancy loss. Am. J. Reprod. Immunol. 2009; 61: 75-84.
  13. Посиссева Л.В., Малышкина А.И., Бойко Е.Л., Сотникова Н.Ю., Перетятко Л.П., Фетисова И.Н. Реабилитация репродуктивного здоровья супружеских пар с невынашиванием беременности. Иваново: «Издательство «Иваново»; 2008. 240с.
  14. Park D.W., Lee H.J., Park C.W., Hong S.R., Kwak-Kim J., Yang K.M. Peripheral blood NK cells reflect changes in decidual NK cells in women with recurrent miscarriages. Am. J. Reprod. Immunol. 2010; 63(2): 173-80.
  15. Beer A.E. New horizons in the diagnosis, evaluation and therapy of recurrent spontaneous abortion. Clin. Obstet. Gynaecol. 1986; 13(1): 115-24.
  16. Chong P.J., Matzner W.L., Ching W.T. Benefit of leukocyte immunizations? Fertil. Steril. 1993; 59(1): 247-9.
  17. Chong P.J., Matzner W.L., Ching W.T. Controversy about immunotherapy. Fertil. Steril. 1993; 59(5): 1138-9.
  18. Robertson S.A., Sharkey D.J. The role of semen in induction of maternal immune tolerance to pregnancy. Semin. Immunol. 2001; 13(4): 243-54.
  19. Малышкина А.И., Можаева А.И., Воронин Д.Н. Особенности реакций врожденного иммунитета у женщин с угрозой прерывания беременности на ранних сроках. Российский иммунологический журнал. 2010; 4: 407-8.
  20. Reznikoff-Etievant M.F., Durieux I., Lobet R., Dambrosio A., Touré C., Dufraisse C. et al. Immunologic abortion and its treatment by immunotherapy. Rev. Fr. Transfus. Immunohematol.1986; 29(3): 135-48.
  21. Лепилова И.Б., Борзова Н.Ю., Сотникова Н.Ю., Крошкина Н.В. Функциональное состояние естественных киллеров в периферической крови и децидуальной оболочке у женщин с невынашиванием беременности ранних сроков. Вестник Российского университета дружбы народов. 2009; 6: 268-72.
  22. Katano K., Suzuki S., Ozaki Y., Suzumori N., Kitaori T, Sugiura-Ogasawara M. Peripheral natural killer cell activity as a predictor of recurrent pregnancy loss: A large cohort study. Fertil. Steril. 2013; 100(6): 1629-34.
  23. Kaczmarek A., Vandenabeele P., Krysko D.V. Necroptosis: The release of damage-associated molecular patterns and its physiological relevance. Immunity. 2013; 38: 209-23.
  24. Крошкина Н.В., Малышкина А.И., Можаева Т.А. Особенности функционального состояния клеток макрофагального ряда у женщин с невынашиванием беременности ранних сроков. Вестник Уральской медицинской академической науки. 2010; 2(1): 154-5.
  25. Liang P., Mo M., Li G.G., Yin B., Cai J., Wu T. et al. Comprehensive analysis of peripheral blood lymphocytes in 76 women with recurrent miscarriage before and after lymphocyte immunotherapy. Am. J. Reprod. Immunol. 2012; 68(2): 164-74.
  26. Lee S.K., Kim J.Y., Lee M., Gilman-Sachs A., Kwak-Kim J. Th17 and regulatory T cells in women with recurrent pregnancy loss. Am. J. Reprod. Immunol. 2012; 67(4): 311-5.
  27. Kwiatek M., Gęca T., Krzyzanowski A., Malec A., Kwasniewska A. Public Peripheral dendritic cells and CD4+CD25+Foxp3+ regulatory T cells in the first trimester of normal pregnancy and in women with recurrent miscarriage. PLoS One. 2015; 10(5): e0124747.
  28. Wang W.J., Hao C.F., Lin Q.D. Dysregulation of macrophage activation by decidual regulatory T cells in unexplained recurrent miscarriage patients. J. Reprod. Immunol. 2011; 92(1-2): 97-102.
  29. Vacca P., Cantoni C., Vitale M., Prato C., Canegallo F., Fenoglio D. et al. Crosstalk between decidual NK and CD14+ myelomonocytic cells results in induction of Tregs and immunosuppression. Proc. Natl. Acad. Sci. USA. 2010; 107(26): 11918-23.
  30. Trabanelli S., Ocadlikova D., Evangelisti C., Parisi S., Curti A. Induction of regulatory T cells by dendritic cells through indoleamine 2,3-dioxygenase: a potent mechanism of acquired peripheral tolerance. Curr. Med. Chem. 2011; 18(15): 2234-9.
  31. Clark D.A., Wong K., Banwatt D., Chen Z., Liu J., Lee L. et al. CD200-dependent and nonCD200-dependent pathways of NK cell suppression by human IVIG. J. Assist. Reprod. Genet. 2008; 25(2-3): 67-72.
  32. Haas D.M., Ramsey P.S. Progestogen for preventing miscarriage. Cochrane Database Syst. Rev. 2008; (2): CD003511.
  33. Карп Г. Систематический обзор применения дидрогестерона для лечения угрозы прерывания беременности. Здоровье женщины. 2013; 1: 46-56.
  34. Check J.H. A practical approach to the prevention of miscarriage: part 2--active immunotherapy. Clin. Exp. Obstet. Gynecol. 2010; 37(1): 5-9.
  35. Сухих Г.Т., Ванько Л.В. Иммунология беременности. М.: Издательство РАМН; 2003. 400с.
  36. Hayakawa S., Karasaki-Suzuki M., Itoh T., Ishii M., Kanaeda T., Nagai N. et al. Effects of paternal lymphocyte immunization on peripheral Th1:Th2 balance and TCR Vb and Vg repertoire usage of patients with recurrent spontaneous abortions. Am. J. Reprod. Immunol. 2000; 43(2): 107-15.
  37. Check J.H., Arwitz M., Gross J., Peymer M., Szekeres-Bartho J. Lymphocyte immunotherapy (LI) increases serum levels of progesterone induced blocking factor (PIBF). Am. J. Reprod. Immunol. 1997; 37(1): 17-20.
  38. Yang H., Qiu L., Di W., Zhao A., Chen G., Hu K., Lin Q. Proportional change of CD4+CD25+ regulatory T cells after lymphocyte therapy in unexplained recurrent spontaneous abortion patients. Fertil. Steril. 2009; 92(1): 301-5.
  39. Khonina N.A., Broitman E.V., Shevela E.Y., Pasman N.M., Chernykh E.R. Mixed lymphocyte reaction blocking factors (MLR-Bf) as potential biomarker for indication and efficacy of paternal lymphocyte immunization in recurrent spontaneous abortion. Arch. Gynecol. Obstet. 2013; 288(4): 933-7.
  40. Nonaka T., Takakuwa K., Ooki I., Akashi M., Yokoo T., Kikuchi A., Tanaka K. Results of immunotherapy for patients with unexplained primary recurrent abortions--prospective non-randomized cohort study. Am. J. Reprod. Immunol. 2007; 58(6): 530-6.
  41. Wilczyhski J.R., Radwan P., Tchorzewski H., Banasik M. Immunotherapy of patients with recurrent spontaneous miscarriage and idiopathic infertility: does the immunization-dependent Th2 cytokine overbalance really matter? Arch. Immunol. Ther. Exp. (Warsz.). 2012; 60(2): 151-60.
  42. Beaman K.D., Ntrivalas E., Maliers T.M., Jaiswal M.K., Kwak-Kim J., Gilman-Sachs A. Immune etiology of recurrent pregnancy loss and its diagnosis. Am. J. Reprod. Immunol. 2012; 67(4): 319-25.
  43. Carp H.J.A., ed. Reccurent pregnancy loss: causes, controversies and treatment. Informa UK ltd.; 2007.
  44. Raj Rai. Debate: Should immunotherapy be used? No. In: Carp H.J.A., ed. Recurrent pregnancy loss: сauses, controversies, and treatment. 2nd ed. CRC Press; 2014: 265.
  45. Duckitt K., Qureshi A. Recurrent miscarriage. BMJ Clin. Evid. (Online). 2011; 2011: pii1: 409.
  46. Gharesi-Fard B., Zolghadri J., Foroughinia L., Tavazoo F., Samsami Dehaghani A. Effectiveness of leukocyte immunotherapy in primary recurrent spontaneous abortion (RSA). Iran. J. Immunol. 2007; 4(3): 173-8.
  47. Bandey M.K., Agrawal S. Induction of MLR-Bf and protection of fetal loss: a current double blind randomized trial of paternal lymphocyte immunization for women with recurrent spontaneous abortion. Int. Immunopharmacol. 2004; 4 : 289-98.
  48. Петросян Л.А. Оптимизация лимфоцитоиммунотерапии в лечении привычной потери беременности первого триместра: автореф. дисс.. канд. мед. наук. М.; 2009. 24с.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies